{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
histamine
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Embramine or mebrophenhydramine is an antiallergic agent. Embramine is a histamine H₁-receptor antagonist exerting anticholinergic activity. It may inhibit stimulated platelet functions by inhibiting phospholipase A2. It is prescribed for severe allergic conditions.
Class (Stereo):
CHEMICAL (ACHIRAL)
Moxastine is a diarylmethane derivative with an antihistamine and anticholinergic activities.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Conessine is a plant steroid alkaloid that acts as a potent and specific antagonist of histamine H3 receptors. Conessine displayed high affinity at both rat and human H3 receptors (pKi = 7.61 and 8.27) and generally high selectivity against other sites, including histamine receptors H1, H2, and H4. Conessine was found to efficiently penetrate the CNS and reach very high brain concentrations. Although the very slow CNS clearance and strong binding to adrenergic receptors discouraged focus on conessine itself for further development, its potency and novel steroid-based skeleton motivated further chemical investigation. Modification based on introducing diversity at the 3-nitrogen position generated a new series of H3 antagonists with higher in vitro potency, improved target selectivity, and more favorable drug-like properties. Conessine also has high affinity for the adrenergic receptors. Conessine has being shown to possess anti-malarial activity. In India conessine finds therapeutic use for treatment of dysentery and helminthic disorders.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Embramine or mebrophenhydramine is an antiallergic agent. Embramine is a histamine H₁-receptor antagonist exerting anticholinergic activity. It may inhibit stimulated platelet functions by inhibiting phospholipase A2. It is prescribed for severe allergic conditions.
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Clocinizine is an antihistamine derivative of diphenylmethylpiperazine. Clocinizine is a competitive and reversible H1 receptor antagonist. The drug is marketed in Spain under tradename Senioral in combination with phenylpropanolamine for temporary relief of nasal congestion in colds, rhinitis, and sinusitis.
Status:
Class (Stereo):
CHEMICAL (RACEMIC)
Mequitamium iodide (LG 30435) is a quaternary ammonium phenothiazine. Mequitamium iodide was found to bind with high affinity only to histamine H1 receptors and to muscarinic acetylcholine receptors. The (+)-(S)-enantiomer is 10-fold more potent than (-)-(R)-enantiomer as a histamine antagonist, while the two enantiomers show the same antimuscarinic activity in vitro. In animal models, it exerts antiasthmatic and antiallergic properties. It was being clinically investigated as a treatment of asthma and rhinitis.
Status:
Investigational
Source:
INN:closiramine [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Clorisamine is an antihistamine drug developed by Schering in the 1970s. The drug was evaluated in phase 1 clinical trial on healthy volunteers. The results show that in a therapeutic dose of 2 mg the drug did not have any effects which might lead to an impairment of driving ability.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Zaltidine (CP-57,361) is a guanidinothiazolylimidazole compound
which is a highly specific H2-receptor antagonist. It potently inhibits gastric acid secretion. Zaltidine appears to be an effective treatment of duodenal ulcer in human studies. However, the incidence of hepatic damage (8%) seems higher than with commonly used H2-receptor antagonists.
Status:
Investigational
Source:
NCT00880217: Phase 2 Interventional Completed Attention Deficit Hyperactivity Disorder
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Bavisant (also known as JNJ-31001074 or BEN-2001), a highly selective, active antagonist of the human H3 receptor that was invented by Johnson & Johnson for the treatment of attention-deficit hyperactivity disorder (ADHD). However, the result of clinical trials did not display significant clinical effectiveness in the treatment of adults with ADHD. BenevolentAI has started phase II clinical trials where investigated bavisant for ameliorating the excessive daytime sleepiness in patients with Parkinson’s disease, using one of the drug side effects is dose-dependent insomnia.
Class (Stereo):
CHEMICAL (ACHIRAL)
Napactadine is a bicyclic antidepressant agent. It is a histamine-H1 receptor antagonist. Preliminary results indicated a marked
improvement in depressive symptomalology within 7 days
of treatment, as measured by the Hamilton depression
scale. However, clinical studies were discontinued after chronic administration of napactadine because an
elevation in liver enzyme levels was observed in some
patients.
